Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disproxil

- PMLiVE

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Analysts predict the drug could be worth $8.7bn in the next five years

- PMLiVE

Type 2 diabetes market set to soar to $64bn by 2026

Rising prevalence, progressive nature and diagnosis of the condition behind the surge

- PMLiVE

Novo Nordisk bolsters management team

Appoints Camilla Sylvest and Doug Langa

Sanofi reception

Solid start for Dupixent as Sanofi raises 2017 outlook

Analysts predict dermatology medicine could become a €5bn product if approved in other indications

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

Sanofi reception

Sanofi and Ablynx sign €2.4bn nanobody deal

The duo will develop immune-mediated inflammatory disease candidates

Sanofi: Wearables are a core part of our digital trials strategy

Pharma firm partners with Parexel on patient sensor work

- PMLiVE

Novo launches personalised diabetes management mobile app

Partners with Glooko on app that syncs blood glucose and activity data

- PMLiVE

Sanofi to pay $750m for vaccines biotech Protein Sciences

Adds US firm's recombinant-based influenza vaccine to its portfolio

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

Sanofi reception

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

The IL-6 inhibitor will be used in combination with methotrexate for adults with RA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links